ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2819

Administration Of a Multi-Epitope Citrullinated Peptide Attuneuates adjuvant  Induced Arthritis In Rats Via Induction Of Immune Tolerance

Howard Amital1, Smadar Gertel2 and Yehuda Shoenfeld3, 1The Zabludowicz Center For Autoimmune Diseases, and Department of Medicine 'B',, Sheba Medical Center,Tel-Hashomer, Tel-Aviv University, Tel-hashomer, Israel, 2The Zabludowicz Center For Autoimmune Diseases, and Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel, 3Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University,Tel-Aviv, Tel-Aviv, Israel

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: ACPA, adjuvant arthritis, Apoptosis, citrullination and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Animal Models II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Antigen-induced peripheral tolerance is a potentially efficient and specific therapeutic approach to attenuate autoimmunity. Citrullinated peptides are major targets of disease-specific autoantibodies in Rheumatoid Arthritis (RA). Currently, citrullinated peptides serve primarily as biomarkers for the diagnosis of RA by measuring titers of anti-citrullinated protein antibodies.

In an attempt to develop a citrullinated peptides-based specific immunotherapy for RA, we previously showed the potential of two citrullinated peptides (citrullinated-filaggrin and citrullinated-β-fibrinogen) to up-regulate TGF-β mRNA expression and concomitant expansion of regulatory T cell population. In addition, our citrullinated peptides reduced the expression of inflammatory cytokines (INF-γ, TNF-α and IL-17), reduced the percentage of pathogenic IL-17+ cells and increased the apoptosis rate of T cells following incubation with RA-derived peripheral blood mononuclear cells (PBMC).

In view of the multiplicity of citrullinated target autoantigens in RA we tailored a multi-epitope citrullinated peptide (Cit-ME) derived from major prevalent citrullinated autoantigens (citrullinated filaggrin, fibrinogen, vimentin and collagen type II). The later was tested for treatment of adjuvant induced arthritis (AIA) via immune tolerance induction by attenuating the disease manifestations. 

Methods: Seven days following induction of AIA in Lewis female rats we administrated Cit-ME (300mg/rat) by 8 subcutaneous injections given on alternate days. Clinical scoring was performed once a week during the experiment. At the end of the experiment rats spleens were analyzed for apoptosis of CD4+ T cells by flow cytomety.

Results: Treatment with Cit-ME ameliorated the clinical score of the diseased arthritic rats.

Rats treated with the Cit-ME had significantly less arthritic symptoms compared to untreated rats at day 21 (Figure 1). Amelioration of disease manifestations was associated with increased apoptosis rate of T cells.

Conclusion: We demonstrated that citrullinated peptides induced immune tolerance in an experimental model of AIA.

Figure 1. Treatment with Cit-ME suppressed Adjuvant induced arthritis (AIA) clinical score in Lewis rats

 


Disclosure:

H. Amital,
None;

S. Gertel,
None;

Y. Shoenfeld,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/administration-of-a-multi-epitope-citrullinated-peptide-attuneuates-adjuvant-induced-arthritis-in-rats-via-induction-of-immune-tolerance/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology